2 unknown, 1 completed, 1 terminated, 1 withdrawn. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Terminated 1, Withdrawn 1 |
Follow Cellworks Group Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports Cellworks Report - Cancer, Relapsed Cancer | Unknown | Cellworks Group Inc. | 730 | 2022-12-01 | 2023-01-23 | |
| A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients Cellworks Singula and Ventura reports - Pan-cancer | Unknown | Avera McKennan Hospital & University Health Center | 730 | 2022-01-01 | 2023-07-19 | |
| iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction - Myelodysplastic Syndromes | Not applicable | Withdrawn | University of Florida | 2019-05-01 | 2019-06-11 | |
| Beat AML Core Study Acute Myeloid Leukemia | Completed | University of Florida | 22 | 2017-02-15 | 2020-08-05 | |
| iCare for Cancer Patients Molecular diagnostic testing - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Not applicable | Terminated | University of Florida | 136 | 2015-06-26 | 2019-12-20 |
Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Recurrence (2) · Leukemia (1) · Multiple Myeloma (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1)
Cytarabine (1) · Molecular Diagnostic Techniques (1) · Palliative Care (1)
United States (5)
Christopher R. Cogle, MD (2) · Christopher Cogle, MD (1) · Scott Howard, M.D. (1) · Tobias Meissner, Dr. sc. hum. (1)